Physician profile
Michael Anthony Stephens
NPI 1801888607
$11,419.96
in general payments reported to CMS, 2019-2025
63 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,342 · 2020: $1,350 · 2021: $1,900 · 2022: $1,815 · 2023: $1,666 · 2024: $1,678 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,012.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,195.87 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,144.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,132.43 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $918.07 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $623.80 | 2019-2025 | |
| Lilly USA, LLC | $580.51 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $471.00 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $416.02 | 2019-2023 | Belsomra |
| Glaxosmithkline, LLC. | $408.20 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $390.78 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $385.09 | 2021-2025 | |
| Astellas Pharma US INC | $356.68 | 2019-2024 | Myrbetriq, Veozah |
| Otsuka America Pharmaceutical, INC. | $305.87 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $300.34 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.40 | 2019-2024 | Jardiance, Ofev |
Show all 57 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.